Company intelligence / Profile preview

Jianenglong Pharmaceutical Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

CanDragon (Beijing) Pharmaceutical Technology is a clinical-stage biotechnology company based in China that focuses on the development of innovative metabolic and endocrine therapies. The company is primarily known for its work on multi-agonist peptides and small molecules targeting the GLP-1, GIP, and glucagon receptors for the treatment of obesity and type 2 diabetes. Its lead programs include dual and triple agonists designed to provide superior weight loss and glycemic control compared to existing mono-therapies. CanDragon operates primarily within the Chinese market but aims to expand its clinical development globally through strategic partnerships.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Jianenglong Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jianenglong Pharmaceutical Technology.

Explore the full profile